Top experts discuss the most important takeaways and data to come out of this year’s ASCO Annual Meeting in non–small cell lung cancer.
Commentary|Articles|June 12, 2026
Targeted Therapies, Frontline Combos Headline Key Lung Cancer Data to Emerge From ASCO 2026
Author(s)Caroline Seymour
Fact checked by: Tracy Ann Politowicz, Chris Ryan
Experts recap of the most pivotal lung cancer data to surface at the 2026 ASCO Annual Meeting.
Advertisement
Advertisement
As data emerged across the non–small cell lung cancer (NSCLC) space at the 2026 ASCO Annual Meeting, experts from the field outlined some of the most crucial findings that could impact future clinical approaches.
Related to this article
Experts go step by step in laying out their thought processes and treatment selections for difficult-to-treat lung cancer cases.
Two decades of biomarker-driven progress have reshaped lung cancer management, but late diagnosis, unequal treatment access, and underfunding remain
Phase 3 data support EGFR and ALK inhibitors as adjuvant standards of care in resectable NSCLC.
Max Diehn, MD, PhD, breaks down how ctDNA testing for MRD is reshaping prognostic discussions in NSCLC.
Five-year outcomes from neoadjuvant, adjuvant, and perioperative immunotherapy trials in resectable NSCLC clarify which patients benefit most.
Sanja Dacic, MD, PhD, outlines advances that are reshaping molecular profiling in advanced non–small cell lung cancer and how to navigate these changes.
Solange Peters, MD, PhD, outlines why docetaxel still anchors second-line therapy in NSCLC and where biomarker retesting could move the field.
Advertisement
Advertisement